TherapeuticsMD Inc (NASDAQ:TXMD) – Investment analysts at Oppenheimer boosted their FY2018 earnings per share (EPS) estimates for TherapeuticsMD in a research note issued on Wednesday, November 7th. Oppenheimer analyst J. Olson now expects that the company will earn ($0.55) per share for the year, up from their previous forecast of ($0.64). Oppenheimer currently has a “Buy” rating and a $14.00 target price on the stock. Oppenheimer also issued estimates for TherapeuticsMD’s FY2019 earnings at ($0.23) EPS, FY2020 earnings at $0.16 EPS, FY2021 earnings at $0.55 EPS and FY2022 earnings at $0.83 EPS.

A number of other research firms have also recently commented on TXMD. Zacks Investment Research cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Friday, August 17th. ValuEngine raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research report on Friday, September 21st. BidaskClub cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Thursday, November 1st. Finally, Cantor Fitzgerald upped their target price on shares of TherapeuticsMD from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Tuesday, August 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $13.45.

NASDAQ TXMD opened at $4.76 on Monday. TherapeuticsMD has a 12 month low of $4.30 and a 12 month high of $7.66. The company has a debt-to-equity ratio of 0.55, a quick ratio of 7.15 and a current ratio of 7.23. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -12.86 and a beta of 1.40.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Wednesday, November 7th. The company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.06. TherapeuticsMD had a negative net margin of 757.59% and a negative return on equity of 102.15%. The company had revenue of $3.47 million for the quarter, compared to analysts’ expectations of $4.43 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. TherapeuticsMD’s revenue for the quarter was down 21.5% compared to the same quarter last year.

In other news, CFO Daniel A. Cartwright sold 40,000 shares of the stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $4.85, for a total transaction of $194,000.00. Following the sale, the chief financial officer now owns 40,000 shares of the company’s stock, valued at $194,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brian Bernick sold 182,800 shares of the stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $6.30, for a total transaction of $1,151,640.00. Following the sale, the director now directly owns 242,000 shares in the company, valued at approximately $1,524,600. The disclosure for this sale can be found here. Insiders have sold 2,381,600 shares of company stock worth $14,032,626 in the last three months. Corporate insiders own 22.85% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of TXMD. Principal Financial Group Inc. lifted its position in shares of TherapeuticsMD by 84.4% during the first quarter. Principal Financial Group Inc. now owns 59,178 shares of the company’s stock worth $288,000 after purchasing an additional 27,081 shares in the last quarter. Xact Kapitalforvaltning AB lifted its position in shares of TherapeuticsMD by 96.3% during the first quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock worth $155,000 after purchasing an additional 15,600 shares in the last quarter. Affiance Financial LLC acquired a new stake in shares of TherapeuticsMD during the second quarter worth about $156,000. Fox Run Management L.L.C. acquired a new stake in shares of TherapeuticsMD during the second quarter worth about $121,000. Finally, Cornerstone Wealth Management LLC acquired a new stake in shares of TherapeuticsMD during the second quarter worth about $6,018,000. 66.24% of the stock is currently owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Further Reading: What is Compound Annual Growth Rate (CAGR)?

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.